The Hypothalamic-Pituitary-Adrenal (HPA) Axis as an Effector System in Weight Regulation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00688987

Recruitment Status : Completed

First Posted : June 3, 2008

Last Update Posted : June 5, 2008

Sponsor:

Information provided by:

Oregon Health and Science University

Study Description

Brief Summary:

Replacing glucocorticoid in a dose dependent manner (including doses within the physiological range) to subjects with adrenal insufficiency will increase visceral fat accumulation independently of total fat mass.

Condition or disease	Intervention/treatment	Phase
Obesity Addison's Disease	Drug: Hydrocortisone Dietary Supplement: Isocaloric Diet	Not Applicable

Detailed Description:

To measure total fat mass by DEXA scan, central (visceral) fat accumulation, insulin sensitivity by FSIVGTT, lipid levels, and adipocyte gene expression in subjects with AI receiving increasing doses of hydrocortisone replacement (15 mg, 25 mg, and 40 mg per day in split doses) for 4-months at a time during ad-lib feeding.

Study Design


Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	24 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Single (Investigator)
Primary Purpose:	Treatment
Official Title:	Cortisol, Central Obesity, and Insulin Resistance: Long Term Studies in Addison's Patients
Study Start Date :	August 2000
Actual Primary Completion Date :	July 2004
Actual Study Completion Date :	August 2004

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: Autoimmune Addison disease

Drug Information available for: Hydrocortisone acetate Hydrocortisone Hydrocortisone sodium succinate Hydrocortisone cypionate Hydrocortisone valerate Hydrocortisone probutate Proctofoam-HC

Genetic and Rare Diseases Information Center resources: Addison's Disease Hypoadrenalism

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: 1 Subjects with AI will be randomized to each of three doses of hydrocortisone for 4 months on each dose.	Drug: Hydrocortisone Subjects will receive in random order daily (split) dosing of hydrocortisone: a low dose of 15 mg (10 in AM, 5 in PM); a medium dose of 25 mg (15 in AM, 10 in PM) and high dose of 40 mg (30 in AM, 10 in PM) for 4 months.
Active Comparator: 2 isocaloric diet	Dietary Supplement: Isocaloric Diet Subjects will eat an isocaloric diet for 4 weeks while taking hydrocortisone Other Name: Weight stable diet

Outcome Measures

Primary Outcome Measures :

Amounts of intra-abdominal fat and total fat at the end of the treatment period for each cortisol dose. [ Time Frame: After 4 months on each dose ]

Secondary Outcome Measures :

Fasting Lipid levels, fat mass by DEXA, post-heparin lipase activity, insulin sensitivity, and fat biopsy [ Time Frame: After 4-months on each dose ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Subjects with complete adrenal failure as defined as spontaneous serum cortisol of levels less than 5 g/dl after 12 hours without glucocorticoid replacement and peak serum cortisol of < 5 g/dl 60 minutes after a 250 g ACTH stimulation test.
Subjects who are at their usual weight (weight stable for at least 1 year)
Subjects on stable replacement doses of any required hormone such as thyroid, sex hormones, mineralocorticoid replacement, growth hormone, and hydrocortisone for at least 6 months, and 4) have a normal body weight (BMI 19-27 kg/m2).

Exclusion Criteria:

Possible confounders on body weight and insulin resistance
Age less than 18 to exclude those who might be experiencing alterations in cortisol production or weight as a result of adolescent growth.
Subjects who exercise > 30 minutes/day, 3 times a week.
Smokers.
Heavy alcohol drinkers (> 2 drinks/ day).
Subjects with medical diagnosis including diabetes, heart disease, and cancer.
Subjects with psychiatric illness (i.e., depression, psychosis, bipolar, schizophrenia; or are taking medications for these disorders).

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00688987

Locations


United States, Oregon
Oregon Health & Science University
Portland, Oregon, United States, 97239

Sponsors and Collaborators

Oregon Health and Science University

More Information


Responsible Party:	Jonathan Q. Purnell, OHSU - The Center for the Study of Weight Regulation
ClinicalTrials.gov Identifier:	NCT00688987 History of Changes
Other Study ID Numbers:	eIRB 545 OCTRI #711
First Posted:	June 3, 2008 Key Record Dates
Last Update Posted:	June 5, 2008
Last Verified:	June 2008

Additional relevant MeSH terms:


Obesity Addison Disease Overnutrition Nutrition Disorders Overweight Body Weight Signs and Symptoms Adrenal Insufficiency Adrenal Gland Diseases	Endocrine System Diseases Autoimmune Diseases Immune System Diseases Hydrocortisone 17-butyrate 21-propionate Hydrocortisone acetate Cortisol succinate Hydrocortisone Anti-Inflammatory Agents

To Top